See on Scoop.itTransparency Market Research

[112 Pages Premium Report] Epigenetics Drugs and Diagnostic Technologies Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 – 2018 – Epigenetics Drugs and Diagnostic Technologies Industry Overview, Market Segmentation…

Transparency Market Research‘s insight:

According to a new market report published by Transparency Market Research "Epigenetics Drugs and Diagnostic Technologies Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018," the global epigenetic drugs and diagnostic technologies market was valued at USD 1.6 billion in 2011 and is estimated to reach a market worth USD 5.7 billion in 2018 at a CAGR of 19.4% from 2012 to 2018.

The growth of the epigenetics market is driven by factors such as increase in aging population, as there is a strong correlation between cancer and aging. According to WHO, it is estimated that global population over the age of 60 years would double from 11% (2000) to 22% (2050). People aged 60 and above are more prone to cancer. Hence, countries are advocating early detection of cancer through screening kits (Epi Procolon, Epi ProLung) which are driving the epigenetic drugs and diagnostic technologies market.

Browse Report :

Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to various disease states. The inhibitors, DNA methyltransferase (DNMT) and Histone Deacetylase (HDAC) are responsible for regulating the cellular expression. Out of the two inhibitors, DNMT accounts for a larger share as these inhibitors offer an improved access for targeting the cancerous cells. Currently, four drugs are approved by FDA and are commercially available. Two of them are DNMT inhibitors: Celgene’s Vidaza (azacitidine) and Eisai’s Dacogen (decitabine) for the treatment of Myelodysplastic Syndrome (MDS), and the other two are HDAC inhibitors: Merck’s Zolinza (vorinostat) and Celgene’s Istodax (romidepsin) both for treatment of Cutaneous T Cell Lymphoma (CTCL).

Epigenetics is a rapidly developing field not only in oncology but also in non-oncology indications (Alzheimer’s and arthritis). Due to the increase in disease identification, manufacturers are taking initiatives in development of varied epigenetic diagnostic techniques. DNA methylation technique in the diagnostic segment accounts for the largest share as compared to histone modification techniques, as the research on DNA methylation has been carried out since decades, and is thus mostly preferred. Furthermore, with the corresponding advancements in research and technology, histone code hypothesis technique came into existence only in late 1980s. Hence, with the surge in interest, there is also an increase in investment for the research and development of histone modifications.

North America accounts for the largest share of the epigenetics market. It is expected that North America will dominate around half of the global epigenetics market due to increasing incidence of cancer and other non-oncology indications. Oncology and other non-oncology indications (Alzheimer’s and arthritis) are associated with epigenetics; thus the increasing incidence of cancer supports the growth of the epigenetics market. Asia accounts for nearly half of the new cancer cases worldwide.

The rising incidence of cancer cases in the Asian region would boost the demand for epigenetic drugs and diagnostic technologies in this market. Australia, China, Japan and South Korea are the largest markets for these therapies. Japan dominates the epigenetics market in Asia-Pacific due to a significant presence of companies in the therapeutics segment such as Eisai Pharmaceuticals and Oncolys Biopharma. These companies are taking initiatives for the development and commercialization of epigenetic drugs. Various research institutes and investments from these companies would drive the epigenetics market.

Some of the key players in this market include Celgene Corporation, Merck, Eisai Pharmaceuticals, Exact Sciences, Epigenomics and others. Manufacturers are entering into strategic alliances with numerous research institutions and other players for the development and commercialization of new and innovative drugs, which might see new players in the market looking to carve out a share of the market for themselves.

The epigenetics drugs and diagnostic technologies market is segmented as follows:

Epigenetics Drugs Market, by Mechanism of Action DNMT InhibitorsEpigenetics Diagnostic Technologies Market, by Types DNA Methylation

           Chromatin Immunoprecipitation (ChIP) Technology

Epigenetics Technologies Market, by Geography North America, Europe Asia-Pacific,RoW


See on